[go: up one dir, main page]

WO2008033304A3 - Compositions for promoting non-leaky collateral vascularization - Google Patents

Compositions for promoting non-leaky collateral vascularization Download PDF

Info

Publication number
WO2008033304A3
WO2008033304A3 PCT/US2007/019670 US2007019670W WO2008033304A3 WO 2008033304 A3 WO2008033304 A3 WO 2008033304A3 US 2007019670 W US2007019670 W US 2007019670W WO 2008033304 A3 WO2008033304 A3 WO 2008033304A3
Authority
WO
WIPO (PCT)
Prior art keywords
leaky
compositions
promoting non
collateral vascularization
vascularization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/019670
Other languages
French (fr)
Other versions
WO2008033304A2 (en
Inventor
Richard J Gregory
Canwen Jiang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of WO2008033304A2 publication Critical patent/WO2008033304A2/en
Publication of WO2008033304A3 publication Critical patent/WO2008033304A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/71—Fusion polypeptide containing domain for protein-protein interaction containing domain for transcriptional activaation, e.g. VP16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention encompasses recombinant nucleic acid molecules encoding chimeric transactivator proteins and their use in promoting non-leaky collateral vascularization. The invention is also directed to methods of treating disorders characterized by increased vascular permeability.
PCT/US2007/019670 2006-09-12 2007-09-11 Compositions for promoting non-leaky collateral vascularization Ceased WO2008033304A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82539606P 2006-09-12 2006-09-12
US60/825,396 2006-09-12

Publications (2)

Publication Number Publication Date
WO2008033304A2 WO2008033304A2 (en) 2008-03-20
WO2008033304A3 true WO2008033304A3 (en) 2008-07-03

Family

ID=39060222

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/019670 Ceased WO2008033304A2 (en) 2006-09-12 2007-09-11 Compositions for promoting non-leaky collateral vascularization

Country Status (2)

Country Link
AR (1) AR062762A1 (en)
WO (1) WO2008033304A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016069760A1 (en) * 2014-10-31 2016-05-06 Steven Yu Method of treating dementia by intranasal administration of vegf gene therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127361A1 (en) * 1997-12-04 2006-06-15 Genzyme Corporation Compositions and methods for inducing gene expression

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127361A1 (en) * 1997-12-04 2006-06-15 Genzyme Corporation Compositions and methods for inducing gene expression

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Annual Meeting of the German-Society-for-Microcirculation-and-Vascula r-Biology, Rostock, GERMANY, September 15 -17, 2005", JOURNAL OF VASCULAR RESEARCH, vol. 43, no. 1, 31 October 2005 (2005-10-31), & ANNUAL MEETING OF THE GERMAN-SOCIETY-FOR-MICROCIRCULATION-AND-VASCULA R-BIOLOGY; ROSTOCK, GERMANY; SEPTEMBER 15 -17, 2005, pages 27 - 58, XP002478670, ISSN: 1018-1172 *
ANONYMOUS: "Clinical trial: Safety and efficacy study of Ad2/hypoxia inducible factor (HIF)-1alpha/VP16 gene transfer in patients with intermittent claudication", INTERNET, 25 July 2005 (2005-07-25), XP002478665, Retrieved from the Internet <URL:http://goldbamboo.com/topic-a141096.html> [retrieved on 20080424] *
CARROLL VERONICA A ET AL: "Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function: implications for targeting the HIF pathway.", CANCER RESEARCH 15 JUN 2006, vol. 66, no. 12, 15 June 2006 (2006-06-15), pages 6264 - 6270, XP002478669, ISSN: 0008-5472 *
ELSON D A ET AL: "Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha.", GENES & DEVELOPMENT 1 OCT 2001, vol. 15, no. 19, 1 October 2001 (2001-10-01), pages 2520 - 2532, XP002478666, ISSN: 0890-9369 *
PAJUSOLA KATRI ET AL: "Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer.", THE FASEB JOURNAL : OFFICIAL PUBLICATION OF THE FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY AUG 2005, vol. 19, no. 10, August 2005 (2005-08-01), pages 1365 - 1367, XP002478667, ISSN: 1530-6860 *
RAJAGOPALAN SANJAY ET AL: "Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience.", CIRCULATION 13 MAR 2007, vol. 115, no. 10, 13 March 2007 (2007-03-13), pages 1234 - 1243, XP002478671, ISSN: 1524-4539 *
RIVARD A ET AL: "Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF.", THE AMERICAN JOURNAL OF PATHOLOGY FEB 1999, vol. 154, no. 2, February 1999 (1999-02-01), pages 355 - 363, XP002959461, ISSN: 0002-9440 *
TRENTIN DIANA ET AL: "Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 21 FEB 2006, vol. 103, no. 8, 21 February 2006 (2006-02-21), pages 2506 - 2511, XP002478668, ISSN: 0027-8424 *
VINCENT K A ET AL: "Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor", CIRCULATION, AMERICAN HEART ASSOCIATION, DALLAS, TX, US, vol. 102, no. 18, 31 October 2000 (2000-10-31), pages 2255 - 2261, XP002225125, ISSN: 0009-7322 *

Also Published As

Publication number Publication date
WO2008033304A2 (en) 2008-03-20
AR062762A1 (en) 2008-12-03

Similar Documents

Publication Publication Date Title
WO2010020766A3 (en) Interleukin fusion polypeptides
WO2010017196A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
PH12019500644A1 (en) Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections
WO2008101985A3 (en) Amino acid sequences directed against vascular endothelial growth factor and polypeptides comprising the same for the treatment of conditions and diseases characterized by excessive and/or pathological angiogenesis or neovascularization
WO2010006060A3 (en) Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
DE602007011171D1 (en) Composition and process for the preparation of steviol glycosides
WO2007024715A3 (en) Dual variable domain immunoglobin and uses thereof
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2008024188A8 (en) Dual variable domain immunoglobulin and uses thereof
WO2008074840A3 (en) Amino acid sequences directed against a metalloproteinase from the adam family and polypeptides comprising the same for the treatment of adam-related diseases and disorders
WO2012088608A8 (en) Compositions comprising natriuretic peptides and methods of use thereof
WO2009149189A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2009134776A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2009149185A3 (en) Dual variable domain immunoglobulins and uses thereof
WO2011039368A3 (en) Dll4-binding molecules
WO2005118644A3 (en) Binding molecules capable of neutralizing rabies virus and uses thereof
WO2007090569A8 (en) Conditioned blood composition and method for its production
WO2011123830A3 (en) Alpha 1-antitrypsin compositions and methods of making and using same
WO2010045388A3 (en) Use of mmp-9 and mmp-12 binding proteins for the treatment and prevention of systemic sclerosis
WO2010077422A3 (en) Formulations of single domain antigen binding molecules
EA201071300A1 (en) ANTIBODIES TO CXCR4
WO2007123765A3 (en) Neutrokine-alpha and neutrokine-alpha splice variant
UA96141C2 (en) Neutralising antibody having specificity for human il-6
WO2012135671A3 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
WO2010142551A8 (en) Amino acid sequences directed against receptors to cytokines belonging to the il-17 family

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07837977

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07837977

Country of ref document: EP

Kind code of ref document: A2